Biotech Values

[mcbio]

Re: NS5A HCV inhibitors

[Unlike ABT-450, on which Enanta is partnered with ABT, EDP-239 is wholly owned by Enanta, a small private company. Other companies with NS5A inhibitors for HCV include BMY, GSK, VRTX, and Presidio Pharma. (The NS5A program from AZN might no longer be active—see #msg-47300638.)]

Don't forget IDIX. ; )